Please download the dossier by clicking on the dossier button x
×

Therapeutic molecules binding PSMA

  • US 20200131274A1
  • Filed: 07/09/2018
  • Published: 04/30/2020
  • Est. Priority Date: 07/10/2017
  • Status: Active Grant
First Claim
Patent Images

1. A binding molecule capable of binding human PSMA comprising a single human variable heavy chain domain (VH) antibody selected from one of the following:

  • a single VH domain antibody comprising a CDR1 sequence comprising SEQ ID NO. 1, a CDR2 sequence comprising SEQ ID NO. 2 and a CDR3 sequence comprising SEQ ID NO. 3;

    a single VH domain antibody comprising a CDR1 sequence comprising SEQ ID NO. 5, a CDR2 sequence comprising SEQ ID NO. 6 and a CDR3 sequence comprising SEQ ID NO. 7;

    a single VH domain antibody comprising a CDR1 sequence comprising SEQ ID NO. 9, a CDR2 sequence comprising SEQ ID NO. 10 and a CDR3 sequence comprising SEQ ID NO. 11;

    a single VH domain antibody comprising a CDR1 sequence comprising SEQ ID NO. 13, a CDR2 sequence comprising SEQ ID NO. 14 and a CDR3 sequence comprising SEQ ID NO. 15;

    a single VH domain antibody comprising a CDR1 sequence comprising SEQ ID NO. 17, a CDR2 sequence comprising SEQ ID NO. 18 and a CDR3 sequence comprising SEQ ID NO. 19;

    a single VH domain antibody comprising a CDR1 sequence comprising SEQ ID NO. 21, a CDR2 sequence comprising SEQ ID NO. 22 and a CDR3 sequence comprising SEQ ID NO. 23;

    a single VH domain antibody comprising a CDR1 sequence comprising SEQ ID NO. 25, a CDR2 sequence comprising SEQ ID NO. 26 and a CDR3 sequence comprising SEQ ID NO. 27;

    a single VH domain antibody comprising a CDR1 sequence comprising SEQ ID NO. 29, a CDR2 sequence comprising SEQ ID NO. 30 and a CDR3 sequence comprising SEQ ID NO. 31;

    a single domain VH domain antibody comprising a CDR1 sequence comprising SEQ ID NO. 33, a CDR2 sequence comprising SEQ ID NO. 34 and a CDR3 sequence comprising SEQ ID NO. 35 or a single VH domain antibody comprising a CDR1 sequence comprising SEQ ID NO. 37, a CDR2 sequence comprising SEQ ID NO. 38 and a CDR3 sequence comprising SEQ ID NO. 39.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×